In line with its growing importance, the (joint) EJNMMI/SNMMI guidelines on PSMA PET and therapy provide comprehensive recommendations for the use of PSMA-based imaging and therapy in clinical practice, further solidifying its role in the management of prostate cancer. The gene discussed is FOLH1; the disease is prostate cancer.